TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

Financial Performance - TScan Therapeutics reported a quarterly loss of $0.28 per share, consistent with the Zacks Consensus Estimate, and unchanged from a year ago [1] - The company posted revenues of $3.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 58.07%, compared to $0.54 million in the same quarter last year [2] - Over the last four quarters, TScan has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance - TScan Therapeutics shares have declined approximately 47% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $2.38 million, and for the current fiscal year, it is -$1.11 on revenues of $9.67 million [7] - The estimate revisions trend for TScan was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact TScan's stock performance [5]